Immune checkpoint therapy for non-small-cell lung cancer: An update

Immunotherapy

Volumn 8, Issue 3, 2016, Pages 279-298

  Xia, Bing ^a   Herbst, Roy S ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

anti CTLA4; anti PD L1; anti PD1; atezolizumab (MPDL 3280A); checkpoint inhibitors; durvalumab (MEDI4736); immunotherapy; ipilimumab; nivolumab; pembrolizumab

Indexed keywords

ATEZOLIZUMAB; B7 ANTIGEN; CANCER VACCINE; CD28 ANTIGEN; DURVALUMAB; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; TICILIMUMAB; VASCULOTROPIN; BLOCKING ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL FUNCTION; CELL INFILTRATION; CELLULAR IMMUNITY; DISEASE COURSE; DISEASE DURATION; DOWN REGULATION; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; MEMORY CELL; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VACCINATION; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; LUNG NEOPLASMS; MULTIMODALITY CANCER THERAPY;

ANIMALS; ANTIBODIES, BLOCKING; ANTIGENS, CD274; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84959363559     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.123     Document Type: Review

References (102)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 64(1), 9-29 (2014
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N. Engl. J.Med. 359(13), 1367-1380 (2008
3. Gettinger S, Herbst RS. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. Cancer J. 20(4), 281-289 (2014
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J.Med. 355(24), 2542-2550 (2006
5. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J.Clin. Oncol. 25(5), 587-595 (2007
6. Denis MG, Vallée A, Théoleyre S. EGFR T790M resistance mutation in non small-cell lung carcinoma. Clin. Chim. Acta 444, 81-85 (2015
7. Chia PL, Mitchell P, Dobrovic A, John T. Prevalence and natural history of ALK positive nonsmall-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin. Epidemiol. 6, 423-432 (2014
8. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J.Clin. Oncol. 27(26), 4247-4253 (2009
9. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat. Rev. Cancer 8(1), 11-23 (2008
10. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer. Res. 14(13), 4275-4283 (2008
11. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012
12. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27(4), 450-461 (2015
13. Anagnostou VK, Brahmer JR. Cancer immunotherapy: a future paradigm shift in the treatment of non-small-cell lung cancer. Clin. Cancer. Res. 21(5), 976-984 (2015
14. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 90, 297-339 (2006
15. Sanmamed MF, Chen L. Inducible expression of B7-H1 (PDL1) and its selective role in tumor site immune modulation. Cancer J. 20(4), 256-261 (2014
16. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256), 1734-1736 (1996
17. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99(19), 12293-12297 (2002
18. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol. Rev. 229(1), 12-26 (2009
19. Howard TA, Rochelle JM, Seldin MF Cd28 and Ctla-4, two related members of the Ig supergene family, are tightly linked on proximal mouse chromosome 1. Immunogenetics 33(1), 74-76 (1991
20. Naluai AT, Nilsson S, Samuelsson L, et al. The CTLA4/CD28 gene region on chromosome 2q33 confers susceptibility to celiac disease in a way possibly distinct from that of type 1 diabetes and other chronic inflammatory disorders. Tissue Antigens 56(4), 350-355 (2000
21. Van Der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J.Exp. Med. 185(3), 393-403 (1997
22. Bluestone JA. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2(6), 555-559 (1995
23. Linsley PS. Distinct roles for CD28 and cytotoxic T lymphocyte-Associated molecule-4 receptors during T cell activation?. J. Exp. Med. 182(2), 289-292 (1995
24. Noel PJ, Boise LH, Thompson CB. Regulation of T cell activation by CD28 and CTLA4. Adv. Exp. Med. Biol. 406 209-217 (1996
25. Rincon M, Flavell RA. AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes. EMBO J. 13(18), 4370-4381 (1994
26. Kalli K, Huntoon C, Bell M, Mckean DJ. Mechanism responsible for T-cell antigen receptor-And CD28-or interleukin 1 (IL-1) receptor-initiated regulation of IL-2 gene expression by NF-kappaB. Mol. Cell. Biol. 18(6), 3140-3148 (1998
27. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 18 621-663 (2000
28. Rudd CE, Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat. Rev. Immunol. 3(7), 544-556 (2003
29. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206(8), 1717-1725 (2009
30. Nirschl CJ, Drake CG. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin. Cancer. Res. 19(18), 4917-4924 (2013
31. Marengere LE, Waterhouse P, Duncan GS, Mittrucker HW, Feng GS, Mak TW Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 272(5265), 1170-1173 (1996
32. Chuang E, Fisher TS, Morgan RW, et al The CD28 and CTLA-4 receptors associate with the serine/threonine phosphatase PP2A. Immunity 13(3), 313-322 (2000
33. Parry RV, Chemnitz JM, Frauwirth KA, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25(21), 9543-9553 (2005
34. Tomasini P, Khobta N, Greillier L, Barlesi F. Ipilimumab: its potential in non-small cell lung cancer. Ther. Adv. Med. Oncol. 4(2), 43-50 (2012
35. Wing JB, Ise W, Kurosaki T, Sakaguchi S Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity 41(6), 1013-1025 (2014
36. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322(5899), 271-275 (2008
37. Hodi FS, O'day SJ, Mcdermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J.Med. 363(8), 711-723 (2010
38. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase II study. J.Clin. Oncol. 30(17), 2046-2054 (2012
39. Ribas A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin. Oncol. 37(5), 450-454 (2010
40. Madureira P, De Mello RA, De Vasconcelos A, Zhang Y. Immunotherapy for lung cancer: for whom the bell tolls?. Tumour Biol. 36(3), 1411-1422 (2015
41. Zatloukal P, Heo D, Park K, et al. Randomized Phase II clinical trial comparing tremelimumab (CP-675, 206) with best supportive care (BSC) following first-line platinumbased therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). Presented at: 45th Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 29 May-2 June 2009
42. Paterson AM, Brown KE, Keir ME, et al. The PD-L1: B7-1 pathway restrains diabetogenic effector T cells in vivo. J. Immunol. 187(3), 1097-1105 (2011
43. Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFRdriven lung tumors. Cancer Discov. 3(12), 1355-1363 (2013
44. Chen N, Fang W, Zhan J, et al. Up-regulation of PD-L1 by EGFR activation mediates the immune escape in EGFRdriven NSCLC: Implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J. Thorac. Oncol. 10(6), 910-923 (2015
45. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosinebased switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173(2), 945-954 (2004
46. Sheppard K-A, Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3 signalosome and downstream signaling to PKC0. FEBS Lett. 574(1), 37-41 (2004
47. Riley JL. PD-1 signaling in primary T cells. Immunol. Rev. 229(1), 114-125 (2009
48. Blazar BR, Carreno BM, Panoskaltsis-Mortari A, et al. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-?-dependent mechanism. J. Immunol. 171(3), 1272-1277 (2003
49. Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM, Soefje SA. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. J. Oncol. Pharm. Pract. 21(6), 451-467 (2014
50. Gunturi A, Mcdermott DF. Nivolumab for the treatment of cancer. Expert Opin. On Invest. Drugs 24(2), 253-260 (2015
51. Spigel DR, Reckamp KL, Rizvi NA, et al. A Phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small-cell lung cancer (NSCLC). ASCO Meeting Abstracts 33(SUPPL 15), 8009 (2015
52. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J.Med. 373(2), 123-135 (2015
53. Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 33(SUPPL 18), LBA109 (2015
54. Gettinger SN, Brahmer JR, Rizvi NA, et al. A Phase III comparative study of nivolumab (anti-PD-1; BMS-963558; ONO-4538) versus docetaxel in patients (pts) with previously treated advanced/metastatic nonsquamous nonsmall-cell lung cancer (NSCLC). ASCO Meeting Abstracts 31(SUPPL 15), TPS8121 (2013
55. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J.Med. 373(17), 1627-1639 (2015
56. Horn L RN, Mazières J, et al. Longer-Term follow-up of a phase 2 study (CheckMate 063) of nivolumab in patients with advanced, refractory squamous non-small-cell lung cancer. Presented at: 16th World Conference on Lung Cancer Denver, CO, USA, 6-9 September 2015
57. Gettinger SN, Hellmann MD, Shepherd FA, et al. First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small-cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. ASCO Meeting Abstracts 33(SUPPL 15), 8025 (2015
58. FDA News Release: FDA approves Keytruda for advanced non-small cell lung cancer. www.fda.gov
59. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372(21), 2018-2028 (2015
60. Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small-cell lung cancer (NSCLC). ASCO Meeting Abstracts 32(SUPPL 15), 8020 (2014
61. Johnson DB, Rioth MJ, Horn L. Immune checkpoint inhibitors in NSCLC. Curr. Treat. Options Oncol. 15(4), 658-669 (2014
62. Herbst RS Baas P Kim DW, et al Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial The Lancet. http://www.thelancet.com
63. Goldberg SB, Gettinger SN, Mahajan A, et al. Activity and safety of pembrolizumab in patients with metastatic non-small-cell lung cancer with untreated brain metastases. ASCO Meeting Abstracts 33(SUPPL 15), 8035 (2015
64. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528), 563-567 (2014
65. Matsumoto K, Fukuyama S, Eguchi-Tsuda M, et al. B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. Biochem. Biophys. Res. Commun. 365(1), 170-175 (2008
66. Akbari O, Stock P, Singh AK, et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol. 3(1), 81-91 (2010
67. CX3CR1 chemokine (C-X3-C motif ) receptor 1 [Homo sapiens (human)]. www.ncbi.nlm.nih.gov/gene
68. Hill JA, Feuerer M, Tash K, et al. Foxp3 transcription-factordependent and-independent regulation of the regulatory T cell transcriptional signature. Immunity 27(5), 786-800 (2007
69. Spigel DR, Chaft JE, Gettinger SN, et al. Clinical activity and safety from a Phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 33(SUPPL 15), 8028 (2015
70. Chaft Je CB, Akerley Wl, et al. Evaluation of PD-L1 expression in metachronous tumor samples and FDG-PET as a predictive biomarker in Ph2 study (FIR) of Atezolizumab (MPDL3280A). Presented at: 16th World Conference on Lung Cancer. Denver, CO, USA, 6-9 September 2015
71. Spira AI, Park K, Mazieres J, et al. Efficacy, safety and predictive biomarker results from a randomized Phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). ASCO Meeting Abstracts 33(SUPPL 15), 8010 (2015
72. Rizvi NA, Chow LQM, Dirix LY, et al. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with nonsmall-cell lung cancer (NSCLC). ASCO Meeting Abstracts 32(SUPPL 15), TPS8123 (2014
73. Brahmer JR, Rizvi NA, Lutzky J, et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. ASCO Meeting Abstracts 32(SUPPL 15), 8021 (2014
74. Rizvi NA, Brahmer JR, Ou S-HI, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell deathligand 1 (PD-L1) antibody, in patients with non-smallcell lung cancer (NSCLC). ASCO Meeting Abstracts 33(SUPPL 15), 8032 (2015
75. Antonia SJ, Gettinger SN, Chow LQM, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim Phase I results. ASCO Meeting Abstracts 32(SUPPL 15), 8023 (2014
76. Callahan MK, Ott PA, Odunsi K, et al. A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. ASCO Meeting Abstracts 32(SUPPL 15), TPS3120 (2014
77. Patnaik A, Socinski MA, Gubens MA, et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small-cell lung cancer (NSCLC): KEYNOTE-021 cohort D. ASCO Meeting Abstracts 33(SUPPL 15), 8011 (2015
78. Gettinger Sn HL, Gandhi L, et al. Long-Term survival, clinical activity and safety of nivolumab (anti-Pd-1; Bms-936558, Ono-4538) in patients (Pts) with advanced non-small cell lung cancer (NSCLC). Presented at: Chicago Multidisciplinary Symposium in Thoracic Oncology (CMTSO) Annual Meeting. Chicago, USA, 30 October-November 1 2014 (Poster 170
79. Rizvi NA, Garon EB, Patnaik A, et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 32(SUPPL 15), 8007 (2014
80. Rizvi NA, Chow LQM, Borghaei H, et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. ASCO Meeting Abstracts 32(SUPPL 15), 8022 (2014
81. Papadimitrakopoulou V, Patnaik A, Borghaei H, et al. Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced nonsmall cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. ASCO Meeting Abstracts 33(SUPPL 15), 8031 (2015
82. Liu SV, Powderly JD, Camidge DR, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinumbased doublet chemotherapy in patients with advanced nonsmall-cell lung cancer (NSCLC). ASCO Meeting Abstracts 33(SUPPL 15), 8030 (2015
83. Antonia SJ, Brahmer JR, Gettinger SN, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small-cell lung cancer (NSCLC). ASCO Meeting Abstracts 32(SUPPL 15), 8113 (2014
84. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin. Cancer Res. 19(5), 1021-1034 (2013
85. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4(127), 127ra137-127ra137 (2012
86. Crino L, Weder W, Van Meerbeeck J, Felip E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(SUPPL 5), v103-v115 (2010
87. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 136(1), 260-271 (2009
88. Velcheti V, Schalper KA, Carvajal DE, et al. Programmed death ligand-1 expression in non-small-cell lung cancer. Lab. Invest. 94(1), 107-116 (2014
89. Kohrt HE, Thielens A, Marabelle A, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123(5), 678-686 (2014
90. Buchan SL, Manzo T, Flutter B, et al. OX40-And CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence. J. Immunol. 194(1), 125-133 (2015
91. Ganesan AP, Johansson M, Ruffell B, et al. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma. J. Immunol. 191(4), 2009-2017 (2013
92. Gibney GT, Hamid O, Gangadhar TC, et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. ASCO Meeting Abstracts 32(SUPPL 15), 3010 (2014
93. Bauer TM, Papadopoulos KP, Autio KA, et al. A firstin-human study of pegylated recombinant human IL-10 (AM0010), daily administered for four months in selected advanced solid tumors. ASCO Meeting Abstracts 32(SUPPL 15), TPS3126 (2014
94. Ribas A, Hanson DC, Noe DA, et al. Tremelimumab (CP-675, 206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12(7), 873-883 (2007
95. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J.Med. 369(2), 134-144 (2013
96. Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br. J. Cancer 112(9), 1421-1427 (2015
97. Sundar R, Cho BC, Brahmer JR, Soo RA. Nivolumab in NSCLC: latest evidence and clinical potential. Ther. Adv. Med. Oncol. 7(2), 85-96 (2015
98. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J.Med. 366(26), 2455-2465 (2012
99. Creelan BC. Update on immune checkpoint inhibitors in lung cancer. Cancer Control 21(1), 80-89 (2014
100. Hanaizi Z, Van Zwieten-Boot B, Calvo G, et al. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur. J. Cancer 48(2), 237-242 (2012
101. Kelly RJ, Gulley JL, Giaccone G. Immunotherapy for non-smallcell lung cancer. Clin. Lung Cancer 11(4), 228-237 (2010
102. Li C XX, Wang H, Wei B (2012) Pd-1 and Ctla-4 mediated inhibitory signaling for T cell exhaustion during chronic viral infections. J.Clin. Cell. Immunol. doi: 10.4172/2155-9899.S12-010 (2012